HOME > TOP STORIES
TOP STORIES
-
REGULATORY AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President
January 12, 2022
-
REGULATORY MHLW Eyes Evaluation Indices and Guidelines to Fuel Rollout of SaMD and Cell & Gene Therapies: Official
January 11, 2022
-
REGULATORY Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official
January 7, 2022
-
REGULATORY MHLW to Reshuffle Organization by Summer to Further Support Drug Development; Economic Affairs Division to Be Renamed
January 7, 2022
-
ORGANIZATION FPMAJ to Go Full Force on Honebuto Debate towards Next Off-Year Price Revision: Chief
January 6, 2022
-
BUSINESS Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
-
BUSINESS Nexium and Feburic Generic Debuts Eyed in 2022, but with Caution to Avoid Shortages
January 5, 2022
-
REGULATORY Japan Govt to End Observational Avigan Study for COVID-19
January 5, 2022
-
BUSINESS 5 Atopic Dermatitis Drugs Debut in Japan since 2018; Focus Now on Roles of Dupixent, JAK Inhibitors
December 28, 2021
-
TRENDS 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
-
TRENDS Top 10 PHARMA JAPAN Articles in 2021
December 28, 2021
-
REGULATORY Japan Approves Lenvima/Keytruda Pair, Opdivo Label Expansion
December 27, 2021
-
REGULATORY Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
-
REGULATORY Ronapreve Given to Nearly 37,000 People in Japan by November, Xevudy to 270: MHLW
December 24, 2021
-
REGULATORY Japan Seeks Additional Study for Aducanumab, Next Review Might Be Few Years Off
December 23, 2021
-
REGULATORY Gist of FY2022 Drug Pricing Reform
December 22, 2021
-
REGULATORY Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
-
COMMENTARY Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
December 20, 2021
-
BUSINESS Astellas to Abolish Pay Structure for Sales Reps, Switching to Company-Wide System Next April
December 20, 2021
-
BUSINESS Pfizer Agrees to Supply Oral COVID-19 Drugs for 2 Million People in Japan
December 20, 2021
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
